PDF(Pubmed)
Abstract：
OBJECTIVE: The RNA binding protein quaking (QKI) is associated with the development and progression of tumor suppressors in various cancers. However, the clinical implications of QKI expression have not yet been fully elucidated. In this study, we aimed to investigate the clinicopathological and prognostic significance of QKI expression in hepatocellular carcinoma (HCC).
METHODS: We performed QKI, Zinc finger E-box-binding homeobox 1 (ZEB1), E-cadherin, and glutathione peroxidase 4 (GPX4) immunohistochemical staining on 166 HCC patient tissue samples. X-tile bioinformatics software was used to set the cut-off value for high QKI expression. Correlations between QKI expression and various clinicopathological parameters were assessed.
RESULTS: The best cut-off value for high QKI expression was 12.5. High QKI expression was observed in 28 of 166 patients (16.9%) and was an independent prognostic factor for inferior recurrence-free survival (RFS). In addition, high ZEB1 and GPX4 expression correlated with high QKI expression, but not with the loss of E-cadherin expression.
CONCLUSIONS: High QKI expression was identified in HCCs and associated with poor RFS. QKI might be a prognostic biomarker of HCCs associated with epithelial-to-mesenchymal transition and a potential candidate therapeutic target.
METHODS: We performed QKI, Zinc finger E-box-binding homeobox 1 (ZEB1), E-cadherin, and glutathione peroxidase 4 (GPX4) immunohistochemical staining on 166 HCC patient tissue samples. X-tile bioinformatics software was used to set the cut-off value for high QKI expression. Correlations between QKI expression and various clinicopathological parameters were assessed.
RESULTS: The best cut-off value for high QKI expression was 12.5. High QKI expression was observed in 28 of 166 patients (16.9%) and was an independent prognostic factor for inferior recurrence-free survival (RFS). In addition, high ZEB1 and GPX4 expression correlated with high QKI expression, but not with the loss of E-cadherin expression.
CONCLUSIONS: High QKI expression was identified in HCCs and associated with poor RFS. QKI might be a prognostic biomarker of HCCs associated with epithelial-to-mesenchymal transition and a potential candidate therapeutic target.
摘要：
目的：RNA结合蛋白（QKI）与多种肿瘤抑制因子的发生发展有关。然而,QKI表达的临床意义尚未完全阐明.在这项研究中,我们旨在探讨QKI在肝细胞癌（HCC）中的表达及其临床病理和预后意义。
方法：我们执行了QKI，锌指E盒结合homeobox1(ZEB1),E-cadherin,和谷胱甘肽过氧化物酶4（GPX4）对166例HCC患者组织样本进行免疫组织化学染色。使用X-tile生物信息学软件设置高QKI表达的截止值。评估了QKI表达与各种临床病理参数之间的相关性。
结果：高QKI表达的最佳截断值为12.5。在166例患者中有28例（16.9％）观察到高QKI表达，并且是劣质无复发生存率（RFS）的独立预后因素。此外,ZEB1和GPX4高表达与QKI高表达相关，但不与E-cadherin表达的丧失有关。
结论：在HCC中发现高QKI表达，并与不良RFS相关。QKI可能是与上皮-间质转化相关的HCC的预后生物标志物和潜在的候选治疗靶标。
方法：我们执行了QKI，锌指E盒结合homeobox1(ZEB1),E-cadherin,和谷胱甘肽过氧化物酶4（GPX4）对166例HCC患者组织样本进行免疫组织化学染色。使用X-tile生物信息学软件设置高QKI表达的截止值。评估了QKI表达与各种临床病理参数之间的相关性。
结果：高QKI表达的最佳截断值为12.5。在166例患者中有28例（16.9％）观察到高QKI表达，并且是劣质无复发生存率（RFS）的独立预后因素。此外,ZEB1和GPX4高表达与QKI高表达相关，但不与E-cadherin表达的丧失有关。
结论：在HCC中发现高QKI表达，并与不良RFS相关。QKI可能是与上皮-间质转化相关的HCC的预后生物标志物和潜在的候选治疗靶标。
